Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection

Nat Genet. 2023 Mar;55(3):471-483. doi: 10.1038/s41588-023-01307-z. Epub 2023 Mar 9.

Abstract

Identification of host determinants of coronavirus infection informs mechanisms of viral pathogenesis and can provide new drug targets. Here we demonstrate that mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) chromatin remodeling complexes, specifically canonical BRG1/BRM-associated factor (cBAF) complexes, promote severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and represent host-directed therapeutic targets. The catalytic activity of SMARCA4 is required for mSWI/SNF-driven chromatin accessibility at the ACE2 locus, ACE2 expression and virus susceptibility. The transcription factors HNF1A/B interact with and recruit mSWI/SNF complexes to ACE2 enhancers, which contain high HNF1A motif density. Notably, small-molecule mSWI/SNF ATPase inhibitors or degraders abrogate angiotensin-converting enzyme 2 (ACE2) expression and confer resistance to SARS-CoV-2 variants and a remdesivir-resistant virus in three cell lines and three primary human cell types, including airway epithelial cells, by up to 5 logs. These data highlight the role of mSWI/SNF complex activities in conferring SARS-CoV-2 susceptibility and identify a potential class of broad-acting antivirals to combat emerging coronaviruses and drug-resistant variants.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Angiotensin-Converting Enzyme 2 / genetics
  • COVID-19* / genetics
  • Chromatin
  • DNA Helicases / genetics
  • Humans
  • Nuclear Proteins / genetics
  • SARS-CoV-2
  • Transcription Factors / genetics

Substances

  • Angiotensin-Converting Enzyme 2
  • Chromatin
  • DNA Helicases
  • Nuclear Proteins
  • SMARCA4 protein, human
  • Transcription Factors

Supplementary concepts

  • SARS-CoV-2 variants